Tilray, Inc. - Class 2 Common Stock (TLRY): Commentary News

TLRY – House Judiciary Committee has enough votes to pass Medical Cannabis Research Act.

Key Facts Surrounding This News Item

  • TLRY had returned 0.00% year-to-date leading up to today’s news, versus a +9.26% return from the benchmark S&P 500 during the same period.

More Info About Tilray, Inc. – Class 2 Common Stock (TLRY)

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was founded in 2018 and is based in Nanaimo, Canada. View our full TLRY ticker page with ratings, news, and more.

TLRY at a Glance

TLRY Current POWR Rating™
Overall POWR Rating™
TLRY Current Price $85.61 3.29%
More TLRY Ratings, Data, and News

TLRY Price Reaction

The day of this event (Sep. 13, 2018)
TLRY Closing Price$119.76 14.11%
TLRY Volume21,827,400
207.93% from avg
Leading up to this event
TLRY 1-mo return293.59%
After this event
TLRY 1-day return3.76%
TLRY 3-day return32.28%
TLRY 5-day return40.49%

TLRY Price Chart

The Top Stocks For 2019

More Tilray, Inc. - Class 2 Common Stock (TLRY) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All TLRY News
Page generated in 0.6702 seconds.